CCT-417

CCT-417 is a small interfering RNA (siRNA) therapeutic candidate being developed by Canary for the treatment of rare pediatric obesity. The drug is designed to address leptin resistance by modulating the expression or activity associated with the leptin receptor (LEPR). Leptin is a critical hormone in the regulation of energy homeostasis and appetite; resistance to its signaling is a primary driver of severe, early-onset obesity in certain genetic and clinical contexts. By utilizing siRNA technology, CCT-417 aims to restore leptin sensitivity, potentially offering a targeted intervention for pediatric patients who do not respond to conventional weight management strategies. The program is currently in the preclinical stage of development.